In brief
A significant shift in federal policy from the National Institutes of Health (NIH) is raising alarms among the scientific community. The newly implemented guidelines prohibit U.S.-based scientists from allocating federal grant funds to foreign collaborators, a move that jeopardizes numerous ongoing international research projects focused on cancer treatment and other vital conditions.
One notable project that stands to be affected is an initiative aimed at extending the lives of women battling the most common form of breast cancer. Up to one-fifth of women with estrogen-responsive breast cancer face potentially fatal recurrences even years after achieving remission. Identifying these at-risk patients early could lead to timely interventions utilizing existing medications, but collaboration with researchers in Denmark is now in jeopardy due to the new NIH restrictions.The NIH's recent policy halts funding for projects that include sub-awards to foreign researchers, impacting thousands of international studies reliant on cross-border partnerships. The agency justified the change by citing difficulties in tracking sub-award payments, a concern reiterated in reports by the Government Accountability Office."This lack of visibility is unacceptable and is exactly why radical change is needed," an NIH official noted in a communication, even though stricter oversight measures had been implemented in 2023 in response to a critical GAO report. The decision by the NIH has sparked intense debate, as researchers express concerns over the potential stagnation of crucial studies that could lead to healthcare advancements beneficial to American patients and the global community alike.
